Skip to main content
. 2024 Apr 12;9(4):102988. doi: 10.1016/j.esmoop.2024.102988

Figure 2.

Figure 2

Disease-free survival effect of TSR in the UNITED cohort and subgroup analyses. (A) Kaplan–Meier analysis and log-rank test showing worse 3-year disease-free survival rates for stroma-high patients in the whole UNITED cohort (70% versus 83%, respectively; P < 0.001). (B) Kaplan–Meier analysis with log-rank test in stage II patients receiving adjuvant chemotherapy, illustrating the worse 3-year survival rates for stroma-high patients despite treatment, indicating potential resistance to adjuvant chemotherapy (stroma-high 73% versus stroma-low 92%; P = 0.008). (C) Kaplan–Meier analysis with log-rank test in stage III patients receiving adjuvant chemotherapy, again illustrating the worse 3-year survival rates for stroma-high patients despite treatment (stroma-high 66% versus stroma-low 80%; P = 0.011). (D) The ASCO criteria (high risk versus low risk) not distinguishing any disease-free survival difference (high risk 91% versus low risk 90%; P = 0.529). (E) Kaplan–Meier analysis with log-rank test in stage II patients not receiving adjuvant chemotherapy, showing significant worse 3-year survival rates in stroma-high patients compared to stroma-low patients (stroma-high 80% versus stroma-low 93%; P < 0.001). (F) Kaplan–Meier analysis with log-rank test, showing overall worse survival in the stroma-high groups despite the short median follow-up of 3 years instead of 5 years, with the curves already diverging at 3 years. The 5-year overall survival rates are 74% versus 83%, respectively (P = 0.102). ASCO, American Society for Clinical Oncology; TNM, tumor–node–metastasis; TSR, tumor–stroma ratio; UNITED, Uniform Noting for International application of the Tumor-stroma ratio as Easy Diagnostic tool.aFor disease-free survival, the number of patients starting can be lower due to missing data.